PER 3.85% 13.5¢ percheron therapeutics limited

EQUITY RESEARCH REPORT - WILSON dated 18 Jan 2022, page-88

  1. 798 Posts.
    lightbulb Created with Sketch. 235
    Hi Dave, nice to read a post from you again.
    I suspect many investors share your thoughts and have had similar experiences with the ups and downs of the market. It's certainly not an easy game and unless you are an FNP (financially knowledgeable person) with lots of time to read and analyse, luck plays a big part in small company investments............... particularly in the biotech space.
    It's interesting to see ANP have a bit of a lift recently against losses in most other notable biotechs but I sense in the many months and years ahead we will surely see some low lows .......... which may present a very good buying opportunity while the science remains excellent as it is now.
    I read all the research and commentary on the various ANP threads from our very knowledgeable HC posters but don't post much myself as I have only amateur medical knowledge which wont add much to any thread. Also I would probably harp back to my concern about media coverage which wont achieve anything.
    Meanwhile I am doing pretty good medically. I have had a CR (Complete Response) to my combined treatments and am cancer free although still continuing with Chemo daily.
    Thanks for asking Dave........there are nice people on HC even though we may have very different opinions on what our companies should be doing about things.smile.png
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.